Aubagio vs Tecfidera
Side-by-side cost comparison based on Medicare Part D data
Aubagio
Teriflunomide
Manufactured by Sanofi
Tecfidera
Dimethyl Fumarate
Manufactured by Biogen
Aubagio costs 18% less per claim than Tecfidera ($3,363.00 vs $4,103.00). A generic version of Aubagio is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Aubagio | Tecfidera |
|---|---|---|
| Avg Cost Per Claim | $3,363.00 | $4,103.00 |
| Total Medicare Spending | $1.3B | $1.8B |
| Total Beneficiaries | 34,000 | 38,000 |
| Total Claims | 386,000 | 428,000 |
| Annual Cost/Patient | $38,176.00 | $46,211.00 |
| Year-over-Year Change | -5.6% | -28.4% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Apr 12, 2024 |
| Manufacturer | Sanofi | Biogen |
| Condition | Multiple Sclerosis | Multiple Sclerosis |
| Generic Name | Teriflunomide | Dimethyl Fumarate |
Aubagio vs Tecfidera: What the Data Shows
Aubagio (Teriflunomide) and Tecfidera (Dimethyl Fumarate) are both used to treat multiple sclerosis. Based on Medicare Part D data, Aubagio costs $3,363.00 per claim, which is 18% less than Tecfidera at $4,103.00 per claim.
Medicare spent $1.3B on Aubagio and $1.8B on Tecfidera. In terms of patient reach, Tecfidera serves more beneficiaries (38,000 vs 34,000).
Year-over-year spending changed -5.6% for Aubagio and -28.4% for Tecfidera.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Aubagio is cheaper at $3,363.00 per claim, compared to $4,103.00 for Tecfidera. That makes Aubagio about 18% less expensive per claim based on Medicare Part D data.
Yes, both Aubagio and Tecfidera are used to treat multiple sclerosis. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Teriflunomide and generic Dimethyl Fumarate can offer significant cost savings, typically 80-95% less than the brand name.
Medicare Part D spent $1.3B on Aubagio covering 34,000 beneficiaries, and $1.8B on Tecfidera covering 38,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.
Comparing Aubagio and Tecfidera on U.S. Medicare prescription-drug pricing requires lining up the underlying CMS Medicare Part D Drug Spending data data side by side. The table above runs the comparison on the canonical fields; the narrative below identifies the factor or factors that drive the most meaningful difference between the two.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.